Cancer

EDAP Announces Second Quarter 2023 Financial Results

- Record second quarter and first half revenues of EUR 14.3 million (USD 15.5 million) and EUR 29.1 million (USD…

11 months ago

CancerVAX CEO Ryan Davies Discussed Cancer Immunotherapy with UCLA Physician-Scientist

Dr. Steven Jonas commented about his journey to becoming both a practicing cancer doctor and active cancer researcherLEHI, Utah, Aug.…

11 months ago

Mithra prices private placement to raise EUR 20 million in equity

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA…

11 months ago

Press Release Biocartis Group NV: Biocartis Announces 2023 Half-Year Results on 26 September 2023

PRESS RELEASE: 24 August 2023, 07:00 CEST BIOCARTIS ANNOUNCES 2023 HALF-YEAR RESULTS ON 26 SEPTEMBER 2023 Mechelen, Belgium, 24 August 2023 –…

11 months ago

BioSenic receives a Chinese patent with broad claims, protecting the combined use of metal ions and arsenic salts to treat a wide range of serious diseases

INSIDE INFORMATION Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administrationEnriched IP…

11 months ago

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: • 2023…

11 months ago

MDxHealth Reports Q2 and Half Year 2023 Results

NEWS RELEASE – REGULATED INFORMATION23 AUGUST 2023, 4:00PM EDT / 22:00 CET             MDxHealth Reports Q2 and Half Year…

11 months ago

Peak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 PH1 (Novel Payload) ADC in Poster at 2023 AACR Annual Meeting

Pleasanton, CA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a…

11 months ago

Begins Dosing Mb22001 in Phase 2 Clinical Trial in World First Take-Home Microdosing Study in Patients with Depression

World-first take-home approvalsThe first doses of MB22001 have been administered in an 8 week treatment protocolVANCOUVER, BC / ACCESSWIRE /…

11 months ago

Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated…

11 months ago